Constantinescu R.,Gothenburg University |
Andreasson U.,Gothenburg University |
Li S.,Gothenburg University |
Podust V.N.,Ciphergen Biosystems |
And 9 more authors.
Parkinsonism and Related Disorders | Year: 2010
Parkinson's disease (PD) and atypical parkinsonian disorders (APD), including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), are a group of neurodegenerative diseases sharing many similar signs and symptoms but distinguished by their particular clinical features, treatment response, prognosis and mortality. The differential diagnosis may be challenging, especially in early disease stages. Considering the importance of an accurate diagnosis both for clinical management and for research, new diagnostic tools are needed. In this study, we investigated 56 PD, 42 MSA, 39 PSP, 9 CBD patients, and 24 healthy controls. After screening the cerebrospinal fluid (CSF) proteome using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), we identified 4 proteins (ubiquitin [mass-to-charge ratio (m/z) 8590], β2-microglobulin [m/ z 11730], and 2 secretogranin 1 [chromogranin B] fragments [m/z 7260 and m/ z 6250]) that differentiated healthy controls and PD patients from patients with APD. However, they could not differentiate PD patients from controls. As none of these changes were APD subgroup-specific, they most likely reflect the intensity and/or extent of the neurodegenerative process in general. © 2010 Elsevier Ltd.
Jayanthi S.,U.S. National Institutes of Health |
Buie S.,U.S. National Institutes of Health |
Moore S.,Ciphergen Biosystems |
Herning R.I.,U.S. National Institutes of Health |
And 4 more authors.
Molecular Psychiatry | Year: 2010
Marijuana (MJ) is the most commonly used illicit drug in the United States. Its abuse is associated with cognitive dysfunctions and increased resistance to blood flow in the cerebral vasculature. In addition, MJ abuse is associated with increased risks of potentially serious cardiovascular disorders. In the present study, we used the protein chip platform based on surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI-TOF-MS) to test the possibility that MJ abuse might be associated with changes in serum protein levels. Indeed, MJ users showed significant increases in three protein peaks, which were identified as three isoforms of apolipoprotein (apo) C-III. Immunoprecipitation using an apoC-III antibody also validated the identification of the proteins. Marijuana-induced increases in apoC-III levels might occur through chronic stimulation of hepatic cannabinoid receptors (CB1 and/or CB2) by its active ingredient, Δ 9 tetrahydrocannibol (THC). Thus, chronic MJ abuse might cause increased transcription and/or translation of apoC-III in the liver with corresponding changes reflected in the plasma of these patients. In any case, because apoC-III is a cardiovascular risk factor, the increased levels observed in MJ users might explain, in part, the cardiac and cerebral abnormalities reported in these patients. © 2010 Nature Publishing Group All rights reserved.
Cho W.C.S.,Queen Elizabeth Hospital |
Yip T.T.,Ciphergen Biosystems |
Cheng W.W.,Queen Elizabeth Hospital |
Au J.S.K.,Queen Elizabeth Hospital
British Journal of Cancer | Year: 2010
Background:Lung cancer is known as the top cancer killer in most developed countries. However, there is currently no promising diagnostic or prognostic biomarker for lung cancer. This study aims to discover non-invasive differential markers in the serum of lung cancer patients, to determine the protein identity of the candidate biomarker(s), and to investigate any clinical implication of the biomarker(s) concerned.Methods:Blood specimens were collected from 154 pre-operative patients with lung cancer and 35 healthy blood donors with no evidence of lung cancer. Fractionated serum samples were processed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (MS). Candidate biomarker was identified using sodium dodecyl sulphate polyacrylamide gel electrophoresis and tryptic digestion followed by tandem MS fragmentation analysis, which was subsequently validated with immunoassay.Results:A differential protein with m/z 11.6 kDa was detected and identified as an isoform of human serum amyloid A (SAA). It was significantly increased by 1822% in lung cancer patients when compared with the healthy controls, which gave an area under the receiver operator characteristic curve of 0.88. In addition, the protein was also significantly elevated by 77% in lung cancer patients with survival <5 years when compared with patients with survival ≥5 years.Conclusion:There are several functions of the SAA protein, described in the context of inflammation, that are compatible with the mechanism of tumour invasion and metastasis. Our study not only detected increased SAA level in the serum of lung cancer patients but also identified that elevated SAA level may be a non-invasive biomarker useful for the prediction of lung cancer prognosis. © 2010 Cancer Research UK All rights reserved.
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase I | Award Amount: 116.07K | Year: 2005
We will use Proteinchipc Arrays with Surface-Enhanced-Laser-Desorption/Ionization Time-of-Flight Mass Spectrometry to obtain a large-scale profiling of the proteins whose brain expression is affected by sleep loss. ProteinChipc Arrays have been developed and marketed by Ciphergen Biosystems Inc., the "small business" in this proposal. The study will be conducted in fruit flies, rats and migratory sparrows, and sleep recordings and sleep deprivation experiments will be performed in the laboratory of Dr. Chiara Cirelli (University of Wisconsin - Madison), the "academic partner" in this proposal. Rats will be studied after acute and chronic sleep deprivation and sleep restriction, to mimic the different battlefield situations. Both wild-type flies, which show a cognitive deficit after sleep deprivation, and sleep-deprivation resistant mutant flies, which do not, will be studied. Both sparrows during the migratory season (when sustained sleep loss does not cause cognitive impairment) and during the nonmigratory season (when even acute sleep loss does) will be studied. The ability to profile gene expression in the brain of 3 different species, and the use of genetic and natural models of resilience to the negative effects of sleep loss will significantly increase the chance of identifying the best molecular markers of cognitive performance.
Bio Rad Laboratories Inc. and Ciphergen Biosystems | Date: 2006-03-06
diagnostic medical reagents for medical research.